

15 June 2026

High Cost Drugs in Ophthalmology

1. For the 4 months from January to April 2026:, how many unique* patients received the following intra-vitreal treatments for any eye condition:

Aflibercept (Eylea) 1759

Aflibercept (Biosimilars) As above

Bevacizumab 2

Brolucizumab 0

Dexamethasone 31

Faricimab 2967

Ranibizumab 157

Fluocinolone acetonide 18

*Please count a patient only once for any treatment, regardless of how many injections or implants they may have received

2. For the patients above, how many were new to intra-vitreal treatment?
Please provide the patient numbers by the treatments listed below, excluding patients who previously had received any of these treatments.

Aflibercept (Eylea) 116

Aflibercept (Biosimilars) As above

Bevacizumab 0

Brolucizumab 0

Dexamethasone 0

Faricimab 166

Ranibizumab 31

Fluocinolone acetonide 0